Invention Grant
- Patent Title: 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
-
Application No.: US15209731Application Date: 2016-07-13
-
Publication No.: US09688672B2Publication Date: 2017-06-27
- Inventor: Thomas Raymond Caferro , Zhuoliang Chen , Young Shin Cho , Abran Q. Costales , Julian Roy Levell , Gang Liu , James R. Manning , Martin Sendzik , Cynthia Shafer , Michael David Shultz , James Clifford Sutton , Yaping Wang , Qian Zhao
- Applicant: NOVARTIS AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agent Laura Madden
- Main IPC: C07D413/14
- IPC: C07D413/14 ; A61K31/506 ; C07D413/04 ; C07D417/14 ; A61K31/5377
Abstract:
The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
Public/Granted literature
- US20160318915A1 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH Public/Granted day:2016-11-03
Information query
